Following is one of the patent documents most requested by researchers using CAS electronic products.
|
CAS indexed 1998 chemical substances from this document.
CAS subject entries for this document include: Inflammation; Intestine, disease; Skin, neoplasm; and 84 additional concepts. | |
CAPLUS COPYRIGHT 2006 ACS on STN
| TITLE:
| Preparation of tartaric acid functional compounds for the treatment of inflammatory disorders |
| INVENTOR(S):
| Guo, Zhuyan; Orth, Peter; Zhu, Zhaoning; Mazzola, Robert D.; Chan, Tin Yau; Vaccaro, Henry A.; McKittrick, Brian; Kozlowski, Joseph A.; Lavey, Brian J.; Zhou, Guowei; Paliwal, Sunil; Wong, Shing-Chun; Shih, Neng-Yang; Ting, Pauline C.; Rosner, Kristin E.; Shipps, Gerald W. Jr.; Siddiqui, M. Arshad; Belanger, David B.; Dai, Chaoyang; Li, Dansu; Girijavallabhan, Vinay M.; Popovici-Muller, Janeta; Yu, Wensheng; Zhao, Lianyun |
| PATENT ASSIGNEE(S):
| Schering Corporation, USA |
| SOURCE:
| PCT Int. Appl., 889 pp. CODEN: PIXXD2 |
| LANGUAGE:
| English |
PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE
--------------- ---- -------- -------------------- --------
WO 2005121130 A2 20051222 WO 2005-US19131 20050601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
ABSTRACT:
The title compds. I [A = (un)substituted benzimidazol-2-yl, imidazol-2-yl, CONH2, CSNH2; J, E = O, S, NR5 (wherein R5 = H, alkyl, alkylaryl); T = O, S; R10, R20 = H, alkyl, fluoroalkyl; R30 = H, alkyl or R30 and R40, taken together with N to which R40 is attached, are joined to form 4-7 membered (un)substituted heterocyclyl; R40, R50 = H, alkyl; W = [C(R13)2]n (wherein n = 0-5; R13 = H, halo, OH, etc.); X = a bond, alkyl, cycloalkyl, etc.; Y = a bond, O, S, NH, etc.; Z = H, alkyl, aryl, etc.; or their pharmaceutically acceptable salts] which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-.alpha. or combinations thereof, were prepd. E.g., a multi-step synthesis of II, starting from 2,2-dimethyl-[1,3]dioxolane-4R,5R-dicarboxylic acid monomethyl ester and 2-(thien-1-yl)ethylamine, was given. The compds. I were tested against TACE (biol. data given for representative compds. I).
Updated 5/4/2007 9:07:15 AM
